Cagrilintide/semaglutide - Adocia
Alternative Names: CagriSema - Adocia; semaglutide/cagrilintide - ADOCIALatest Information Update: 12 Feb 2025
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetes mellitus; Obesity